Political Integrity Network
HR 4780 · 119th Congress · House

USTRx Act

In committee
IntroducedJul 29, 2025
Policy areaForeign Trade and International Finance
Cosponsors8
What this bill is intended to do

Use Sovereignty To reduce Rx Act or the USTRx Act This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers. The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States. The bill also requires the USTR to submit to Congress a plan to respond to certain adverse acts, policies, or practices of high-income countries that are related to the trade of pharmaceutical products.

Latest action

Jul 29, 2025Referred to the House Committee on Ways and Means.

No grade provided. The Quiet Ledger grades only on a bill's full statutory text, which Congress.gov hasn't published for this bill yet. PIN re-checks automatically and grades it the moment the text appears.